logo-loader
HealthPharma & Biotech
MaxCyte

MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH

microscope
The pair will use MaxCyte's cell engineering platform

MaxCyte Inc (LON:MXCT) shares rose on Monday after it said it has entered into an R&D agreement with the US National Institutes of Health (NIH) to develop treatments for sickle cell disease. 

They will do so using next-generation CRISPR/Cas9-based single-nucleotide correction technologies enabled by MaxCyte's cell engineering platform.

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH.

Correcting mutations

The two hope to "correct" the faulty haemoglobin gene that causes the disease and address DNA mutations that contribute to the disease. 

As part of the tie-up, MaxCyte will supply messenger RNA molecules that convey genetic information from DNA to the ribosomes.

It will also use its Flow Electroporation Technology to develop reliable and effective processes to correct gene sequences.

MaxCyte chief executive Doug Doerfler said: "We believe that this work will further validate our platform for developing gene-editing therapies for a broad range of diseases while enabling rapid, development and commercial manufacturing of new therapies for patients where there is an extremely high unmet medical need."

In early morning trading, Maxcyte shares were up 1.6% at 249p.

-- Adds share price --

 

Quick facts: MaxCyte

Price: £1.22

Market: AIM
Market Cap: £69.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read